💊 医薬品 A-Z 🧬 標的 🛠 ツール 📚 ガイド
全医薬品 薬物分類 治療領域 副作用
ガイド 用語集 年表
比較 薬物の体内の旅 薬物ファミリー
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Tovorafenib

CHEMBL3348923 Phase 4 承認済み Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
506.3 g/mol
LogP
3.0
Phase
4

Tovorafenib is an oral, brain-penetrant, RAF kinase inhibitor that selectively inhibits BRAF monomers and dimers (including BRAF V600E mutations and certain non-V600E alterations) by functioning as a type II RAF inhibitor, blocking MAPK pathway-driven tumor cell proliferation. It is approved for pediatric patients with relapsed or refractory BRAF-altered pediatric low-grade glioma, and is under investigation for adult BRAF-altered cancers including colorectal and bladder cancers. Its once-weekly dosing and CNS penetration distinguish it from other RAF inhibitors.

分子量

506.3000 g/mol

LogP

3.00

TPSA

164.00 Ų

リピンスキーの五則

不適合

治療領域

Melanoma Pancreatic Cancer Bladder Cancer Thyroid Cancer Colorectal Cancer Leukemia

作用機序

Inhibits BRAF kinase, a key component of the RAS/MAPK signaling pathway, blocking constitutive activation that drives cancer cell proliferation in tumors harboring BRAF mutations.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

Inhibits BRAF kinase, a key component of the RAS/MAPK signaling pathway, blocking constitutive activation that drives cancer cell proliferation in tumors harboring BRAF mutations.

2D構造

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1

                

                

                
                

                    
InChI

                    
InChI=1S/C17H12Cl2F3N7O2S/c1-6(28-15(31)12-11(19)13(23)27-5-26-12)16-25-4-9(32-16)14(30)29-10-2-7(17(20,21)22)8(18)3-24-10/h2-6H,1H3,(H,28,31)(H2,23,26,27)(H,24,29,30)/t6-/m1/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C17H12Cl2F3N7O2S

                    

                    
                    

                        
HBD / HBA

                        
3 / 11

                    

                    
                    

                        
回転可能結合数

                        
5

                    

                    
                    
                    

                        
重原子数

                        
32

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
よくある質問

                

                    
                    

                        
                        

                            
Tovorafenib is an oral, brain-penetrant, RAF kinase inhibitor that selectively inhibits BRAF monomers and dimers (including BRAF V600E mutations and certain non-V600E alterations) by functioning as a type II RAF inhibitor, blocking MAPK pathway-driven tumor cell proliferation. It is approved for pediatric patients with relapsed or refractory BRAF-altered pediatric low-grade glioma, and is under investigation for adult BRAF-altered cancers including colorectal and bladder cancers. Its once-weekly dosing and CNS penetration distinguish it from other RAF inhibitors.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Inhibits BRAF kinase, a key component of the RAS/MAPK signaling pathway, blocking constitutive activation that drives cancer cell proliferation in tumors harboring BRAF mutations.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Tovorafenib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL3348923.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 25161177.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
医学的免責事項

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.